Key Drivers
- Strong Liquidity
- Heavy R&D
- Rich Valuation
AIAI Summary
BMRN has evolved from a straightforward VOXZOGO-led growth story into an execution-dependent integration and margin-expansion case after the Amicus deal, and despite strong cash flow and a solid balance sheet, the stock likely needs clear proof that higher revenue is translating into cleaner earnings before its premium valuation can re-rate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy R&D
- •Rich Valuation
BMRN is financially stable and cash-generative with strong liquidity and free cash flow, but heavy operating/R&D spending and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower-highs
- •Support break
- •Weak rebound
BMRN is in a short-term downtrend, trading near the bottom of its last month range after breaking $52.6–$53.5 support, and it needs to reclaim $53.5–$54.0 to stabilize, with $55.46 the key upside trigger.
Broke below support on 2026-05-15 after a series of weaker rebounds
Sentiment & News
Key News Insights:
- •Acquisition boost
- •Earnings miss
- •Pipeline momentum
BioMarin posted strong revenue growth and raised full-year guidance after the Amicus acquisition and positive VOXZOGO data, but earnings missed expectations due to higher costs and charges.
The news is modestly positive for BioMarin's longer-term outlook, but near-term share performance may stay capped by margin pressure and the earnings miss
Similar Companies in Healthcare
Other companies in the same sector with AI ratings